Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali
| Autor: | Patrick L.F. Zuber, Samba O. Sow, Téné M. Yaméogo, Lawrence H. Moulton, Uma Onwuchekwa, Modibo Keita, Anna P. Durbin, Massambou Sacko, Neal A. Halsey, Kirsten S. Vannice, Saad B. Omer, Fabien Diomandé |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
Adult medicine.medical_specialty MenAfriVac Adolescent Drug-Related Side Effects and Adverse Reactions The Meningitis Vaccine Project: The Development Licensure Introduction and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Developing country Meningococcal Vaccines Meningococcal vaccine Mali Mass Vaccination meningitis belt Young Adult meningococcal vaccine Conjugate vaccine Environmental health Product Surveillance Postmarketing Medicine Humans vaccine safety Child business.industry Public health Incidence Infant The Development Licensure and Introduction of Menafrivac medicine.disease Clinical trial Vaccination Infectious Diseases Child Preschool PsA-TT Immunology business Malaria |
| Zdroj: | Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |
| ISSN: | 1537-6591 |
| Popis: | New vaccines, such as those against malaria and dengue, are being developed for use primarily in low-resource countries. Emerging manufacturers provide an increasingly large volume of vaccine products to global programs that will never reach industrialized country markets [1]. Concerted efforts are being made to reduce the time from availability of new vaccines, such as rotavirus and human papillomavirus vaccines, to their introduction in developing countries [2]. The current vaccine pipeline includes products based on complex technologies such as genetic recombination or novel adjuvant systems, and theoretical concerns about the safety of new products indicate the need for postlicensure safety monitoring [3, 4]. Public concern about vaccines can also adversely impact vaccination programs, and having systems in place to monitor safety can help address these concerns with reliable data [5]. Most low-income countries do not have the resources or infrastructure in place for postlicensure safety surveillance. PsA-TT is a lyophilized conjugate vaccine developed for use in the meningitis belt of sub-Saharan Africa and manufactured by the Serum Institute of India Ltd [6]. Clinical trials in India and West Africa included nearly 12 000 individuals aged 1–29 years, although at the time of licensure |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|